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Abstract
Mechanisms leading to decreased platelet count in immune thrombocytopenia (ITP) are
heterogeneous. This study describes increased platelet apoptosis involving loss of mito-
chondrial membrane potential (ΔΨm), caspase 3 activation (aCasp3) and phosphatidylser-
ine (PS) externalization in a cohort of adult ITP patients. Apoptosis was not related to
platelet activation, as PAC-1 binding, P-selectin exposure and GPIb-IX internalization were
not increased. Besides, ITP platelets were more sensitive to apoptotic stimulus in terms of
aCasp3. Incubation of normal platelets with ITP plasma induced loss of ΔΨm, while PS
exposure and aCasp3 remained unaltered. The increase in PS exposure observed in ITP
platelets could be reproduced in normal platelets incubated with ITP plasma by adding nor-
mal CD3+ lymphocytes to the system as effector cells. Addition of leupeptin -a cathepsin B
inhibitor- to this system protected platelets from apoptosis. Increased PS exposure was
also observed when normal platelets and CD3+ lymphocytes were incubated with purified
IgG from ITP patients and was absent when ITP plasma was depleted of auto-antibodies,
pointing to the latter as responsible for platelet damage. Apoptosis was present in platelets
from all patients carrying anti-GPIIb-IIIa and anti-GPIb auto-antibodies but was absent in
the patient with anti-GPIa-IIa auto-antibodies. Platelet damage inversely correlated with
platelet count and decreased during treatment with a thrombopoietin receptor agonist.
These results point to a key role for auto-antibodies in platelet apoptosis and suggest that
antibody-dependent cell cytotoxicity is the mechanism underlying this phenomenon.
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Introduction
Immune thrombocytopenia (ITP) is an autoimmune condition in which defects in immune
self-tolerance lead to humoral and cellular abnormal responses comprising auto-antibody pro-
duction and cytotoxic effects [1]. These abnormal immunological patterns are responsible for
increased platelet destruction as well as decreased megakaryopoiesis and thrombopoiesis, [2, 3]
both leading to a thrombocytopenic state.
A large number of studies established the crucial role of auto-antibodies in ITP pathogene-
sis, demonstrating that main platelet antigenic targets are the fibrinogen receptor glycoprotein
complex (GP) IIb-IIIa and the von Willebrand receptor GPIb-IX [4, 5] while a lower propor-
tion of auto-antibodies react with the collagen receptors GPIa-IIa and GPIV [6]. Antibody-
bound-platelet phagocytosis by the reticuloendothelial system is the primary pathogenic mech-
anism by which auto-antibodies induce thrombocytopenia, although lysis mediated by comple-
ment activation on antibody-bound platelets seems to have also a role in ITP [7, 8]. Beyond
auto-antibodies, other mechanism involving direct T-cell mediated cytotoxicity was also
shown to participate in platelet destruction [9, 10].
Similarly to nucleated cells, platelet life span is controlled by an intrinsic apoptotic program,
being major players in this process the anti-apoptotic protein BcL-xL and pro-apoptotic pro-
teins Bak and Bax [11]. Pro- and anti-apoptotic protein unbalance triggers mitochondrial
outer membrane permeabilization (MOMP) that is followed by mitochondrial inner mem-
brane potential collapse (ΔCm), efflux of cytochrome c into the cytoplasm, activation of cas-
pase 3 and 9, phosphatidylserine (PS) externalization and microparticle shedding [12]. Since
some of these events also take place during platelet activation, markers of platelet apoptosis
should be carefully analyzed.
Previous studies have assessed the contribution of platelet apoptosis to ITP pathogenesis.
Platelet apoptosis was first demonstrated in an animal model of ITP, in which injection of anti-
GPIIb antibodies triggered features of platelet apoptosis, including ΔCm, PS exposure and cas-
pase activation, in murine platelets [13]. Concerning human ITP, evidence of platelet apopto-
sis, including caspase 3, 8 and 9 activation, was shown in children with acute ITP, which was
ameliorated by intravenous immunoglobulin infusion [14], whereas another study revealed
that platelets from adult chronic ITP patients displayed increased phosphatidylserine exposure
associated with dendritic cell dysfunction, although other markers of platelet apoptosis could
not be demonstrated in this cohort [15].
The aim of the present work was to deepen into the study of platelet apoptosis in adult ITP
patients, to evaluate its relationship with clinical and biochemical parameters including the
presence and type of auto-antibody, and to investigate possible triggering mechanisms. Our
results provide new evidence involving auto-antibodies as main contributors to platelet apo-
ptosis in ITP.
Materials and Methods
Patients and blood samples
Twenty-four patients with chronic ITP (median age, 42 years, range 21–80) diagnosed accord-
ing to current criteria [16] were included. This project was approved by the Ethics Committee
from Instituto de Investigaciones Médicas “Alfredo Lanari” on May 3, 2010. Clinical and labo-
ratory data are presented in Table 1.
Bleeding score was evaluated according to the ITP Bleeding Scale (IBLS) proposed by Page
and col [17]. Briefly, grade 0 corresponded to no bleeding manifestations, grade 1, to mild
bleeding symptoms assessed in at least one of nine anatomical sites including skin, mucosa,
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gastrointestinal, urinary and gynaecological tract, lungs and central nervous system, and grade
2 corresponded to severe bleeding in at least one of the mentioned anatomical sites.
Blood samples were obtained after written informed consent in accordance with the Decla-
ration of Helsinki as follows: 5 mL were collected into ACD-EDTA (citric acid 71.4 mmol/L,
sodium citrate 85 mmol/L, dextrose 11.1 mmol/L, EDTA 5 mmol/L) for apoptosis studies, 5
mL into 3.8% sodium citrate for activation studies and preparation of recalcified plasma and
2.5 mL into 342 mmol/L EDTA for cell count.
Sample preparation
• Fresh human platelets obtained by differential centrifugation either from ITP patients or nor-
mal volunteers, were washed in CGS Buffer (130 mmol/L ClNa, 12.9 mmol/L sodium citrate,
30 mmol/L glucose, pH 6.5), and resuspended in Binding Buffer (0.01 mol/L Hepes/NaOH,
pH 7.4, 0.14 mol/L NaCl, 2.5 mmol/L CaCl2) to a density of 10
7 platelets/mL.
• Preparation of recalcified plasma, IgG purification and adsorption of auto-antibodies from
ITP plasma were conducted as described previously [3]. Complete depletion of auto-antibod-
ies from platelet-adsorbed (PA) plasma was confirmed by ELISA measurement, as detailed
below. Normal control plasmas were processed simultaneously under the same conditions.
Table 1. Clinical and laboratory data from ITP patients.
Patient Platelets Auto-antibody directed to: BS Treatment
N° (x 109/L) GPIIbIIIa GPIbIX GPIaIIa
1 38 - - - 2 None
2 30 - - - 1 Corticosteroids
3 52 - - + 2 None / Spl.
4 85 - - - 0 Danazol
5 46 - - - 2 None / Spl.
6 6 + - - 2 None
7 30 - - - 1 Corticosteroids
8 16 - + - 2 Corticosteroids/Spl.
9 29 - - - 2 Corticosteroids/Spl
10 50 + - - 1 Corticosteroids
11 30 - - - 1 None
12 22 - - - 2 Cortic/IVIg/Spl
13 63 - - - 2 Corticosteroids
14 8 - - - 2 None / Spl.
15 65 - - - 0 Corticosteroids
16 22 - - - 2 Corticosteroids
17 20 - - - 0 None
18 62 - - - 2 Corticosteroids
19 50 + - - 1 None
20 53 + - + 1 Corticosteroids
21 37 - - - 2 Corticosteroids
22 50 ND ND ND 1 None
23 23 ND ND ND 1 None
24 40 + - - 2 Azathioprine/Spl.
Platelet count and treatment at the time of study. BS: Bleeding scale; Spl: splenectomy; Cortic: Corticosteroids; IVIg: intravenous immunoglobulin; ND: not
done.
doi:10.1371/journal.pone.0160563.t001
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• Apoptosis was evaluated in ITP platelets either unstimulated or with the addition of calcium
ionophore (A23187) (SIGMA, St. Louis, MO) for 3 minutes at room temperature. A23187
final concentrations were 1 to 3 μmol/L, except for active caspase 3 assays, where 6 to
10 μmol/L A23187 were also tested.
• For normal platelet apoptosis studies in the presence of ITP plasma, normal platelets were
resuspended in recalcified either normal or ITP plasma to a final concentration of 107 plate-
lets/mL and incubated at room temperature during 1 hour. Platelets were then washed, resus-
pended in binding buffer and evaluated for apoptosis markers.
• Interaction between normal platelets and autologous normal CD3+ lymphocytes in the pres-
ence of ITP plasma, purified IgG or PA-plasma: normal CD3+ lymphocytes were isolated by
mononuclear cell density gradient centrifugation and subsequent immunomagnetic positive
selection (Miltenyi-Biotec, Bergisch Gladbach, Germany). Cell purity assessed by flow cytome-
try analysis of fluorescein isothiocyanate (FITC)-conjugated CD3 and phycoerythrin (PE)-
conjugated CD45 (both from BD Biosciences, San Diego, CA, USA) was over 98%. Then,
5x105 CD3+ lymphocytes were incubated with 5x106 autologous platelets in 100 μL of either
ITP or control recalcified plasma, as well as its platelet-adsorbed fraction and purified IgG frac-
tion, during 1 hour at 37°C. Cells (CD3+ lymphocytes and platelets) were washed, resuspended
in binding buffer and tested for apoptotic parameters. To analyze the role of antibody depen-
dent cell-mediated cytotoxicity (ADCC) in platelet damage in this system, 20 μmol/L leupeptin
(SIGMA, St. Louis, MO) was also added to inhibit cathepsin B [18–19] that could be released
by CD3+ lymphocytes. Results represent the average of at least two independent experiments.
Apoptosis studies
Phosphatidylserine exposure on the platelet surface: samples were incubated for 15 minutes
with 5 μL (FITC)-conjugated Anexin V (BD Biosciences) and 3 μL PE-conjugated anti-CD41a
(BD Biosciences Pharmingen, San Diego, CA, USA) and acquired within 1h on a FACSCanto
II flow cytometer (BD Biosciences). Results were expressed as percentage of positivity.
Mitochondrial electrochemical potential (ΔCm): loss of ΔCm was determined using the cell
penetrating lipophilic cationic fluorochrome JC-1 (Molecular Probes, Eugene, OR, USA).
Platelets were incubated for 20 minutes with 10 μg/mL JC-1 diluted with PBS supplemented
with 1% BSA and immediately analyzed by flow cytometry. Results were expressed as percent-
age of events with low red fluorescence, reflecting the decrease in the content of JC-1 aggregates
when the inner mitochondrial membrane becomes depolarized.
Active caspase 3: caspase 3 activation was measured by the carboxyfluorescein-labeledfluor-
omethyl ketone tetrapeptide inhibitor of caspase 3 (FAM-DEVD-FMK; Chemicon Interna-
tional, Temecula, CA, USA) that specifically and covalently binds to active caspase 3. Briefly,
105 platelets were incubated in the dark for 1 hour at 370°C with 1:150 diluted FAM-DEVD-
FMK solution. After washing, platelets were analyzed by flow cytometry. Anti-CD42b-PE
(clone HIP1) (BD Biosciences Pharmingen) was used to identify platelet population. Results
were expressed as percentage of platelets with active caspase 3 (aCasp3).
Apoptotic parameters in ITP platelets were considered altered when exceeded the mean+2SD
of control samples. Platelet apoptotic status was defined abnormal when at least two of the three
markers were above the normal limit.
Platelet activation studies
PAC-1 binding and P-selectin expression were evaluated as described elsewhere [20] either in
resting conditions or after stimulation with 20 μmol/L ADP or 20 μmol/L thrombin receptor
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activator peptide (TRAP). For GPIb-IX internalization assay, platelets were fixed with 1% PFA
for 15 minutes. After a washing step, GPIb-IX on the cell surface was identified by incubation
with anti-CD42b-PE and flow cytometry analysis. GPIb-IX internalization was calculated as
percent of decrease in mean fluorescence intensity (MFI) of activated (A) compared to resting
(R) platelets.
Auto-antibody evaluation
Specificity of auto-antibodies was evaluated on EDTA-anticoagulated plasma and, in some
cases, in platelet-adsorbed plasma, processed using PAKAUTO kit (GTI Diagnostics Inc.,
Waukesha, WI, USA), according to the manufacturer´s instructions. This methodology allows
the detection of auto-antibodies (IgG, IgM or IgA subclasses), identifying those directed against
GPIIb-IIIa, GPIb-IX and GPIa-IIa.
Reticulated platelets
The immature platelet fraction was determined by flow cytometry using thiazole orange (TO,
Sigma-Aldrich, St Louis, MO, USA). Briefly, platelets were incubated with TO, 10 ng/mL for 1
hour at RT in the dark. Platelets were identified using PE-conjugated CD41.
Statistical analysis
Data are presented as median and range. Variables were analyzed for normality and equality of
variances using Shapiro-Wilks and F-test, respectively. Differences between data from ITP
samples and normal controls were assessed using unpaired t-test or Mann–Whitney test.
When indicated, groups were compared in a paired way using paired t-test or Wilcoxon signed
rank test. Chi-square or Fisher’s exact test were used to analyze categorical variables. Relation-
ship between two sets of variables was determined by Pearson or Spearman correlation. P val-
ues less than 0.05 were considered statistically significant.
Results
Platelets apoptosis is increased ITP patients
To determine whether platelet apoptosis occurs in our cohort of adult patients with ITP, we
evaluated PS exposure, ΔCm, and levels of active caspase 3 in ITP platelets in resting condi-
tions. Platelets from ITP patients displayed increased PS expression, loss of ΔCm and higher
aCasp3 (Fig 1A). Examples of the apoptotic parameters evaluated in normal and ITP platelets
are shown in Fig 1B–1F.
ITP platelets show increased levels of active caspase 3 after calcium
ionophore stimulation
After stimulation with A23187, a known inducer of apoptosis [21], ITP platelets showed simi-
lar levels of PS expression and ΔCm than normal controls (n = 20 and n = 23, respectively,
both p = NS) (Fig 1G). However, higher sensitivity to the apoptotic stimulus was evidenced by
increased levels of aCasp3 which reached statistical significance at high calcium ionophore
concentrations (n = 12, Fig 1H).
Markers of platelet activation in ITP
Basal levels of platelet activation did not differ between chronic ITP patients and healthy con-
trols when evaluated by PAC-1 binding to GPIIb-IIIa (n = 16). After stimulation with ADP or
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TRAP, PAC-1 binding to ITP platelets tended to be lower than normal controls although dif-
ferences were not statistically significant (n = 16, Fig 2A). ITP platelets did not show increased
expression of P-selectin either in resting conditions or when stimulated with ADP or TRAP
(n = 8, Fig 2B). Moreover, internalization of GPIb-IX after ADP and TRAP stimulation was
similar between patients and controls (n = 9 for both agonists, Fig 2C).
Effect of ITP plasma on apoptosis of normal platelets
In order to test whether a plasmatic factor such as auto-antibodies present in ITP plasma sam-
ples could induce platelet apoptosis by itself, we tested apoptosis parameters in normal platelets
after 1 hour incubation with either ITP or normal plasma. A trend towards higher apoptosis
was observed in normal platelets incubated with ITP plasma compared to those incubated with
normal plasma. This increase was statistically significant only for ΔCm (n = 18, Fig 3A–3C),
which, in our hands represents a more sensitive apoptotic parameter.
Fig 1. Apoptosis markers in ITP platelets. A) Unstimulated platelets from ITP patients were washed and incubated either with
FITC-anexin-V to detect phosphatidylserine (PS) exposure (n = 21), JC-1 to evaluate loss of ΔΨm (n = 24) or FAM-DEVD-FMK
to measure active caspase 3 (aCasp3) (n = 12) as described in Materials and methods. Samples were analyzed by flow
cytometry within 1 hour of processed. Box plot represent percentage of platelets displaying apoptotic markers in ITP patients (P)
and controls (C). Wilcoxon signed rank test *p<0.05, **p<0.01, ***p<0.001. Representative examples of FITC-anexin-V
binding (B), active caspase 3 detection (C, D) and loss of ΔΨmmeasurement (E, F) in control and ITP platelets are shown. G)
Platelet apoptosis was induced by the addition of 1–3 μmol/L A23187 and evaluated by PS exposure (p = NS, n = 20) and ΔΨm
measurement (p = NS, n = 23). H) Active caspase 3 was evaluated after apoptosis induction with 1–3 and 6–10 μmol/L A23187
(p = NS and **p<0.01, respectively).
doi:10.1371/journal.pone.0160563.g001
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Fig 2. Basal and agonist-induced platelet activation in ITP patients.Unstimulated platelets and platelets
activated with 20 μMADP or TRAP were evaluated for (A) GPIIb-IIIa activation by incubation with FITC-PAC-
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Effect of ITP plasma on normal platelet phosphatydilserine expression in
the presence of autologous normal CD3+ lymphocytes
After the finding that ITP plasma had a subtle pro-apoptotic effect on normal platelets in
terms of loss of mitochondrial membrane potential, we tested the ability of ITP plasma to fur-
ther induce PS externalization in normal platelets in the presence of autologous normal CD3+
lymphocytes. To this end, ITP plasma samples from 14 patients (four patients with anti-
GPIIb-IIIa auto-antibodies, one with anti-GPIIb-IIIa and anti-GPIa-IIa auto-antibodies, one
with anti-GPIb-IX auto-antibodies and 8 with no detectable auto-antibodies) along with
plasma from 13 healthy controls were used. Incubation of normal CD3+ lymphocytes with
autologous platelets in the presence of ITP samples induced an increase in platelet PS exposure
compared to cells incubated with normal plasma (Fig 4A). A representative example is shown
in Fig 4B. Platelet granule secretion, as assessed by surface P-selectin expression, in these condi-
tions was similar in samples incubated with ITP and control plasma (data not shown) ruling
out a possible activating effect of ITP samples.
To investigate whether auto-antibodies that could be present in ITP plasma samples could
be responsible for the induction of apoptosis in normal platelets, incubation of these plasmas
with normal platelets was carried out to eliminate auto-antibodies and, then, the platelet-
adsorbed (PA) plasma obtained was tested in our system (normal platelets + autologous nor-
mal CD3+ lymphocytes). In contrast to the original ITP plasma samples, the corresponding
platelet-adsorbed ITP samples were unable to increase PS expression in normal platelets (Fig
4C). Moreover, increased PS exposure was evidenced when purified IgG from ITP samples was
used instead of the corresponding whole plasmas (Fig 4D).
Taken together, these results suggest that ADCC is the responsible for platelet damage. To
confirm this hypothesis, we added leupeptin, a cathepsin B inhibitor [18], to this system to
inhibit the action of one of the main enzymes involved in ADCC. In these conditions, PS expo-
sure was statistically lower than that found in the absence of the inhibitor (Fig 4E).
1 (results are expressed as MFI) and (B) percentage of P-selectin externalization by incubation with
FITC-CD62P. C) Percentage of GPIb-IX internalization was calculated by measuring GPIb-IX expression
before and after agonist-induced platelet activation. None of these parameters were significantly altered in
ITP platelets (P) compared to control platelets (C) (Mann-Whitney test).
doi:10.1371/journal.pone.0160563.g002
Fig 3. Apoptosis markers in normal platelets incubated with ITP plasma. Unstimulated normal platelets were washed
and incubated either with ITP or control plasma during 1 hour. Then, platelets were washed and incubated with FITC-
anexin-V, JC-1 or FAM-DEVD-FMK as described in Materials and Methods, and analysed by flow cytometry within 1hour
of processed. Box plot represent percentage of apoptotic platelets measured as A) PS exposure (Mann-Whitney test
p = NS, n = 10), B) loss of ΔΨm (*p<0.05, n = 12) and C) aCasp3, (p = NS, n = 18).
doi:10.1371/journal.pone.0160563.g003
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Markers of apoptosis in ITP platelets and correlation with biochemical
and clinical data
Platelet count. All apoptotic parameters evaluated in ITP platelets in resting conditions
inversely correlated with platelet count (PS expression, Spearman correlation, R = 0.448,
p = 0.0131; loss of ΔCm, Spearman correlation, R = 0.523, p = 0.0013; aCasp3, Pearson correla-
tion, R = 0.599, p = 0.0394).
Presence and specificity of auto-antibodies. There was a trend for higher incidence of
platelet apoptosis in ITP patients in whom auto-antibodies were detected (86%) than in those
where auto-antibodies could not be found (36%), as assessed by PS exposure (Fisher exact test,
p = 0.063, OR: 10.8, 95% CI = 0.99–117). All patients carrying anti-GPIIb-IIIa auto-antibodies
(n = 5) and the one with anti-GPIb auto-antibodies had increased platelet PS. Interestingly, the
only patient bearing detectable auto-antibodies without increased platelet PS was the one who
had isolated anti-GPIa-IIa auto-antibodies (Fig 5A).
Platelet apoptosis and treatment. Platelet apoptosis parameters were similar when com-
paring untreated patients and patients under any kind of treatment (Fig 5B). However, it must
be considered that patients enrolled in this study had moderate to severe thrombocytopenia
(range 6–85 x 109/L) regardless of treatment condition. In fact, platelet counts were within the
Fig 4. Induction of normal platelet apoptosis by ITP samples in the presence of normal autologous CD3+ lymphocytes.
Unstimulated normal platelets and autologous CD3+ lymphocytes were separately purified and incubated either in ITP or control
samples during 1 hour. Then, samples were washed, incubated with FITC-Anexin-V and analysed by flow cytometry within 1
hour of processed to detect PS exposure. A) Percentage of PS expression on normal platelets incubated with ITP plasma
(n = 14) and control plasma (n = 13) (MannWhitney test, ****p<0.0001) in the presence of autologous CD3+ lymphocytes. B) A
representative example showing percentage of FITC-Anexin-V staining on platelets incubated with ITP plasma and normal
plasma is shown. C) Comparison between fold increase in PS exposure on normal platelets incubated with individual ITP
recalcified plasma (ITP plasma) and its corresponding platelet-adsorbed plasma (PA plasma), both in the presence of autologous
normal CD3+ lymphocytes (Paired t test, p<0.01). Dotted line represents PS exposure of control samples. D) Percentage of PS
expression on normal platelets incubated with autologous CD3+ lymphocytes in the presence of purified IgG from ITP plasma
(n = 8) and control plasma (n = 6) (MannWhitney test, **p<0.01) E) PS exposure induced by ITP plasma samples in the
presence (+) or absence (-) of 20 μmol/L leupeptin (n = 10, paired t test ***p<0.001).
doi:10.1371/journal.pone.0160563.g004
Auto-Antibody Induction of Platelet Apoptosis in ITP
PLOSONE | DOI:10.1371/journal.pone.0160563 August 5, 2016 9 / 14
same range in both groups (35±16 x 109/L in the untreated group and 41±22 x 109/L in the
group receiving any kind of treatment). During the course of this study, PS exposure and ΔCm
were evaluated in platelets from three ITP patients who received eltrombopag, a nonpeptidyl
agonist of the Thrombopoietin receptor (TRA). Both markers decreased during eltrombopag
administration in treated patients when platelet count increased (one had a complete response
and two other had minor increases in platelet counts) although statistical difference was only
observed for ΔCm (Fig 5C).
Bleeding and thrombotic events. Taking into account that PS exposure on platelet mem-
brane could be associated with an increased procoagulant activity, we tried to correlate platelet
Fig 5. Apoptosis in ITP platelets according to clinical and laboratory data. A) ITP patients were grouped according to
the presence/absence of auto-antibodies and increased or normal PS exposure on autologous platelets. The incidence of
platelet apoptosis tended to be higher in patients with auto-antibodies than in those with no-detectable auto-antibodies
(Fisher exact test, p = 0.063, OR: 10.8, 95% CI = 0.99–117). B) The incidence of platelet apoptosis was similar in patients
without treatment and under any kind of treatment (Fisher exact test, p = 1.00, OR: 1.429, 95% CI = 0.271–7.521). C) PS
exposure and loss of ΔΨm before (B) and during eltrombopag treatment (TRA). Data represents mean+SD from three ITP
patients (Paired t test, PS, p = NS; loss of ΔΨm *p<0.05). D) ITP patients were grouped according to their Bleeding scale
(ITP Bleeding Scale-IBLS) and the number of ITP patients with increased platelet apoptosis was plotted in each group (Chi
squared test, p = 0.732).
doi:10.1371/journal.pone.0160563.g005
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apoptosis in ITP patients with thrombotic and bleeding complications. None of the patients in
this cohort experienced thrombotic events, precluding analysis of a potential association
between the procoagulant capacity of platelets and thrombosis. Then, based on the premise
that increased platelet procoagulant activity could protect from bleeding, we searched for a pos-
sible association between platelet apoptosis and the bleeding score. However, no relationship
was found between both parameters in our cohort of ITP (Fig 5D).
Reticulated platelets. Patients with ITP had increased percentage of reticulated platelets
(13.6%, 3.0–32.3%) compared to normal controls (4.8%, 0.6–13.2%), (Wilcoxon rank sum test,
p<0.0001). Levels of reticulated platelet inversely correlated with platelet apoptosis measured
in terms of PS exposure (Spearman corelation, r = -0.6295, p = 0.0039) probably due to the fact
that young platelets are more resistent to apoptosis.
Discussion
In the present study, we demonstrate an apoptotic behavior of platelets from ITP patients, as
assessed by disruption of mitochondrial membrane potential, increased PS exposure and cas-
pase 3 activity. In agreement with data from Alvarez and col [22], PS externalization was not
due to platelet activation because PAC-1 binding and P-selectin expression were normal in ITP
platelets in resting conditions and were not increased after agonist stimulation, while agonist-
induced decrease of GPIb was also normal. Our finding that apoptotic features, such as PS
exposure and altered mitochondrial membrane potential, are linked to caspase 3 activation,
which represents a central step in the apoptotic cascade, together with the absence of platelet
activation indicate that, as previously shown for pediatric acute ITP [14], platelet apoptosis is a
prominent feature of chronic ITP in adult patients.
It is largely recognized that accelerated clearance of auto-antibody-bound-platelets by the
reticulo-endothelial system is responsible for thrombocytopenia in ITP. Although this mecha-
nism is still central for elimination of circulating ITP platelets, other pathologenic mechanisms
were described, including a cytotoxic T-cell lytic effect [9] and impaired platelet production
[3]. Our results show an inverse relationship between loss of ΔCm, increase in aCasp3 and PS
exposure and platelet counts, which highlights the relevance of platelet apoptosis in the devel-
opment of thrombocytopenia in this disorder and further reinforces the fact that heteroge-
neous mechanisms contribute to ITP pathogenesis.
The higher incidence of apoptotic platelets in ITP patients carrying auto-antibodies against
the major platelet glycoproteins suggests a causal role for these antibodies in triggering platelet
apoptosis. Platelet apoptosis was evident in all five ITP patients with anti-GPIIb-IIIa auto-anti-
bodies and the one with anti-GPIb auto-antibodies. The possible link between anti-platelet
antibodies and platelet apoptosis has been previously suggested by Leytin et al [13], who
described that injection of anti-GPIIb antibodies in a murine ITP model triggers thrombocyto-
penia that is associated with platelet apoptosis.
In order to assess the contribution of anti-platelet antibodies to platelet apoptosis, in the
present study we developed a two-step in vitro system to evaluate whether ITP patient plasma
could trigger apoptosis of normal platelets. First, normal platelets were challenged with ITP
plasma and, next, normal platelets were co-incubated with autologous normal CD3+ lympho-
cytes in the presence of ITP plasma. The first approach showed an increased disruption of
mitochondrial membrane potential, as an early apoptotic marker, while PS exposure was not
significantly altered. These results point to a soluble factor as responsible for triggering mito-
chondrial damage. Candidate factors leading to this phenomenon include anti-platelet anti-
bodies and molecules such as TNFα, which could induce apoptosis through the extrinsic
pathway. However, TNFα levels were found decreased in ITP [23]. Besides, the responsibility
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of this non-specific apoptotic factor seems unlikely, since it could induce apoptosis in other
hematopoietic cells, leading to cytopenias other that thrombocytopenia, which is not the case
in ITP. In our working conditions, complement-mediated cytotoxicity after auto-antibody
binding also seems unlikely, since complement was undetectable in recalcified plasma (data
not shown).
In the second approach, ITP plasma was shown to trigger full-blown PS exposure in normal
platelets when co-incubated with autologous normal CD3+ lymphocytes. In this condition,
platelet PS exposure reached similar levels to those observed in circulating platelets from ITP
patients. To investigate if anti-platelet antibodies represent the plasmatic factor responsible for
this effect, we tested the ability of immune-adsorbed plasma as well as purified IgG from ITP to
induce PS exposure in normal platelets in this system. Immunodepletion was able to abolish
the increase in platelet PS exposure caused by the corresponding original unmodified plasma,
while purified IgG reproduced the apoptotic effect. These results point to anti-platelet antibod-
ies as responsible for the observed phenotype. The fact that some of these ITP plasmas were
found negative in the assay used for platelet antibody detection, strongly suggest the presence
of undetected auto-antibodies in these samples and reflect current limitations for platelet auto-
antibody detection in ITP [24].
Previous reports described the contribution of cellular immune mechanisms to ITP platelet
destruction. In this regard, Zhao et al [10] demonstrated that ITP CD8+ lymphocytes induce
platelet apoptosis, involving the participation of HLA type I on CD8+ lymphocytes and an
abnormal platelet self-antigen presentation. In addition, Olsson et al [9] reported that several
cytotoxic genes are overexpressed in ITP CD3+ cells and that CD3+CD8+ cells have a lytic effect
on platelets whereas CD3-CD56+ natural killer cells do not play such a role. In our system,
anti-platelet antibodies seem to be essential for reproducing the apoptotic behavior of ITP
platelets. The fact that plasma-induced platelet apoptosis was maximal in the presence of nor-
mal CD3+ cells points to antibody-dependent cell cytotoxicity as the mechanism underlying
this phenomenon, suggesting that, besides the already reported direct CD8+ cytotoxic effect, T-
cells may mediate ITP platelet destruction by an antibody-dependent mechanism. Among
CD3+ lymphocytes, the γδ fraction could account for this activity [25]. Studies are in progress
to identify the lymphocyte subset responsible for this effect.
Although less frequently than in ITP patients carrying auto-antibodies, 36% of the patients
in whom platelet auto-antibodies could not be detected, also had increased platelet apoptosis.
A possible explanation for this phenomenon could be the presence of auto-antibodies other
than those detected by our method or below the threshold of detection of the assay, at least in
some samples. The fact that immunodepletion was able to revert the pro-apoptotic effect of
plasma and that purified IgG was able to reproduce it, even in those samples without detectable
antibodies, further reinforces this possibility.
Interestingly, the patient with anti-GPIa-IIa did not show platelet apoptosis. This type of
auto-antibodies seems to behave differently than anti-GPIIb-IIIa and GPIb. In a previous
study, we demonstrated that ITP plasma carrying anti-GPIIb-IIIa and GPIb antibodies inhibit
proplatelet formation from normal cord blood-derived megakaryocytes, while anti-GPIa-IIa
auto-antibodies did not. Moreover, collagen was unable to induce the expected inhibition of
proplatelet formation in normal mature megakaryocytes exposed to anti-GPIa-IIa-bearing ITP
plasma [3], suggesting an aberrant intramedullary proplatelet generation. Therefore, thrombo-
cytopenia in these patients seems not be due to platelet apoptosis but to other mechanisms
including abnormalities in platelet production.
Platelet abnormalities decreased during treatment with eltrombopag in three ITP patients
in this study. In constrast to our findings, Álvarez Román and col [22] showed persistent ele-
vated PS expression in patients treated with eltrombopag or romiplostim. Interestingly, Beau
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Mitchell and col. [26] recently described ameliorated sensitivity to platelet apoptosis in a Bcl-
xL inhibitor assay during the first week of treatment with thrombopoietin receptor agonists,
together with activation of the pro-survival Akt signaling pathway, although this improvement
was not sustained on the second week of treatment. Further work regarding the potential anti-
apoptotic effect of thrombopoietin receptor agonists on platelets seems warranted.
In conclusion, this study confirms the relevance of platelet apoptosis in ITP and highlights
the role of auto-antibodies in its development. These findings underscore the fact that diverse
underlying mechanisms contribute to platelet destruction in ITP and emphasize that both
humoral and cellular immune mechanisms, as well as the interplay between them, are involved
in ITP pathogenesis.
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